Pharmacokinetics of clomipramine during pregnancyTer Horst, P. G. J., Proost, J. H., Smit, J. P., Vries, M. T., de Jong-van den Berg, L. & Wilffert, B., Dec-2015, In : European Journal of Clinical Pharmacology. 71, 12, p. 1493-1500 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Pharmacoepidemiology and Pharmacoeconomics
- Pharmacokinetics, Toxicology and Targeting
- Biopharmaceuticals, Discovery, Design and Delivery (BDDD)
- Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE)
- Center for Liver, Digestive and Metabolic Diseases (CLDM)
- Pharmacotherapy and Pharmaceutical Care
- Methods in Medicines evaluation & Outcomes research (M2O)
- Reproductive Origins of Adult Health and Disease (ROAHD)
Clomipramine is one of the drugs for depression during pregnancy; however, pharmacokinetic data of clomipramine and its active metabolite desmethylclomipramine in this vulnerable period are lacking. In this study, we describe clomipramine and desmethylclomipramine concentrations including their ratios during pregnancy. Second, we describe Center for Epidemiologic Studies Depression scale (CES-D) scores during pregnancy.
During 13 pregnancies, every trimester and 3 months after pregnancy, the clomipramine and desmethylclomipramine concentrations were measured with LC-MSMS and the severity of depression was assessed by taking the CES-D score. All concentrations used in our calculations were in fact the ratio between actual plasma concentration (mu g/l) and the actual dose (mg). We compared differences in ratios between trimesters by using the Friedman test.
Studying 12 women and 13 pregnancies, we found no changes in mean clomipramine concentrations, a statistically significant decrease in mean desmethylclomipramine concentrations (p = 0.014) and a significant decrease in the ratio of desmethylclomipramine/clomipramine mean concentrations during pregnancy (p = 0.014) compared to the post-partum period. Sub-therapeutic concentrations of clomipramine and desmethylclomipramine were found in three patients during whole pregnancy.
The mean concentrations of the pharmacologically active metabolite of clomipramine and desmethylclomipramine changes during pregnancy, where a decrease in mean concentrations was found during pregnancy. In case of recurrent disease, we recommend to control clomipramine and its metabolite concentrations, while both are active.
|Number of pages||8|
|Journal||European Journal of Clinical Pharmacology|
|Publication status||Published - Dec-2015|
- Clomipramine, Desmethylclomipramine, Pregnancy, DEPRESSION, PHARMACOGENETICS, PHARMACOMETRICS, ANTIDEPRESSANTS, GUIDELINES, SYMPTOMS, UPDATE